TGA issues SSSI for abatacept

Pharmacists authorised to substitute Orencia 125mg/mL products to deal with shortages  The Therapeutic Goods Administration (TGA) has issued a Serious Scarcity Substitution Instrument (SSSI) in response to shortages of both the Orencia (abatacept) 125mg/mL ClickJect autoinjector for subcutaneous injection and prefilled syringe products.  Bristol-Myers Squibb Australia (BMS) advised the TGA that the two products were